Hester Biosciences Limited (IN:HESTERBIO)
:HESTERBIO
HESTERBIO Stock Chart & Stats
₹1605.75
-₹5.75(-0.24%)
At close: 4:00 PM EST
₹1605.75
-₹5.75(-0.24%)
Day’s Range― - ―
52-Week Range₹1,250.95 - ₹2,347.70
Previous CloseN/A
Volume2.45K
Average Volume (3M)308.00
Market Cap
₹12.15B
Enterprise Value₹14.15B
Total Cash (Recent Filing)₹281.58M
Total Debt (Recent Filing)₹2.14B
Price to Earnings (P/E)38.8
Beta0.71
Next Earnings
May 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.44%
Share Statistics
EPS (TTM)10.30
Shares Outstanding8,506,865
10 Day Avg. Volume428
30 Day Avg. Volume308
Financial Highlights & Ratios
PEG Ratio0.96
Price to Book (P/B)3.84
Price to Sales (P/S)3.88
P/FCF Ratio27.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue & Margin MomentumSustained revenue growth paired with expanding gross, EBIT and EBITDA margins indicates improving unit economics and operational leverage. Over a 2–6 month horizon this supports predictable cash generation and reinvestment capacity, underpinning durable profit expansion.
Strong Cash GenerationConsistent free cash flow growth and a healthy operating cash flow to net income ratio point to good cash conversion and funding flexibility. This durable cash generation reduces refinancing risk, supports capex needs, and enables strategic investments or debt repayment.
Balanced Capital StructureA solid equity base and moderate leverage provide financial flexibility for expansion and withstands cyclical revenue swings. Balanced leverage helps preserve credit access and limits interest burden, supporting medium‑term investment in capacity and R&D without excessive strain.
Bears Say
Rising Debt Needs MonitoringAn increasing debt profile, even from a moderate base, can constrain flexibility if growth slows or margins compress. Over months, higher interest or repayment obligations could limit capex, dividend policy, or require asset-light financing, raising refinancing risk.
Demand Cyclicality From Disease CyclesRevenue dependence on disease incidence and vaccination timing creates structural demand volatility. Outbreak-driven spikes alternate with troughs in normal seasons, making multi‑period planning, capacity utilization and margin predictability more challenging for management.
Regulatory DependencyReliance on regulatory approvals for product commercialization adds structural timing and execution risk. Delays or additional compliance requirements can push back launches and revenue, affecting medium‑term growth trajectories and R&D returns.
Hester Biosciences Limited News
HESTERBIO FAQ
What was Hester Biosciences Limited’s price range in the past 12 months?
Hester Biosciences Limited lowest stock price was ₹1250.95 and its highest was ₹2347.70 in the past 12 months.
What is Hester Biosciences Limited’s market cap?
Hester Biosciences Limited’s market cap is ₹12.15B.
When is Hester Biosciences Limited’s upcoming earnings report date?
Hester Biosciences Limited’s upcoming earnings report date is May 30, 2026 which is in 55 days.
How were Hester Biosciences Limited’s earnings last quarter?
Hester Biosciences Limited released its earnings results on Jan 30, 2026. The company reported ₹10.303 earnings per share for the quarter, beating the consensus estimate of N/A by ₹10.303.
Is Hester Biosciences Limited overvalued?
According to Wall Street analysts Hester Biosciences Limited’s price is currently Overvalued.
Does Hester Biosciences Limited pay dividends?
Hester Biosciences Limited pays a Annually dividend of ₹7 which represents an annual dividend yield of 0.44%. See more information on Hester Biosciences Limited dividends here
What is Hester Biosciences Limited’s EPS estimate?
Hester Biosciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hester Biosciences Limited have?
Hester Biosciences Limited has 8,506,865 shares outstanding.
What happened to Hester Biosciences Limited’s price movement after its last earnings report?
Hester Biosciences Limited reported an EPS of ₹10.303 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.194%.
Which hedge fund is a major shareholder of Hester Biosciences Limited?
Currently, no hedge funds are holding shares in IN:HESTERBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hester Biosciences Limited
Hester Biosciences Limited manufactures and trades in veterinary vaccines and animal health products in India and internationally. It operates in two segments, Poultry Healthcare and Animal Healthcare. The company provides poultry vaccines for diseases, such as newcastle disease, infectious bronchitis, infectious bursal disease, fowl pox, egg drop syndrome, reo, marek's disease, infectious coryza, fowl cholera, mycoplasma gallisepticum, inclusion body hepatitis, avian encephalomyelitis, etc. It also offers vaccines for large animals comprising Goat Pox, Peste des Petits Ruminants, Brucellosis, Mastitis, Metritis, and various infectious diseases, as well as infections, reproductive disorders, theileriosis, parasitic diseases, etc. In addition, the company provides feed supplements, such as toxin binder, trace minerals, enzyme preparation, and bypass fat; disinfectants for farms and equipment, and water sanitizers; nutrition products consisting of mineral mixtures, fertility supplements, and growth tonics; and herbal products, including growth promoters, herbal replacers for choline chloride, stress relievers and immunity boosters, respiratory stimulants, liver tonics, wound healing preparations, uterine tonics, digestive tonics and anti-bloat solutions, ectoparasiticide preparations, anti-mastitis, and anti-prolapse preparations. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Ahmedabad, India.
Technical Analysis
Gufic Biosciences Limited
―
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
―
Unichem Laboratories Limited
―